Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

Pages

12 results
11:50 AM, May 01, 2017  |  BC Extra | Company News

Shire, Parion in deal for ENaC inhibitor for dry eye

Parion Sciences Inc. (Durham, N.C.) granted Shire plc (LSE:SHP; NASDAQ:SHPG) exclusive, worldwide rights to P-321 ophthalmic solution, an epithelial sodium channel (ENaC) inhibitor in development to treat dry eye disease. Parion received $20 million up front...
6:01 PM, Jul 11, 2016  |  BC Extra | Company News

FDA approves Shire's Xiidra

complete response letter. Xiidra is an eye drop formulation of a small molecule integrin beta(2) (LFA-1
6:14 PM, Jan 25, 2016  |  BC Extra | Company News

Shire resubmits lifitegrast NDA

SARcode Bioscience Inc. Lifitegrast is an eye drop formulation of a small molecule integrin beta(2) (LFA-1
6:27 PM, Oct 19, 2015  |  BC Extra | Company News

FDA wants another lifitegrast trial from Shire

16, 2014) . Shire gained the eye drop formulation of a small molecule integrin beta(2) (LFA-1
6:32 PM, Feb 12, 2015  |  BC Extra | Company News

Shire's firepower

amphetamine , and Lifitegrast , an eye drop formulation of a small molecule integrin beta(2) (LFA-1
6:02 PM, Jun 23, 2014  |  BC Extra | Company News

Shire targeting $10B in sales by 2020

an NDA to FDA for the eye drop formulation of a small molecule integrin beta(2) (LFA-1
5:18 PM, May 16, 2014  |  BC Extra | Company News

Shire forms ophthalmic unit, to submit lifitegrast NDA

scores. Shire gained lifitegrast -- an eye drop formulation of a small molecule integrin beta(2) (LFA-1
5:43 PM, Mar 25, 2013  |  BC Extra | Company News

Shire acquiring dry eye company SARcode

undisclosed milestones. Shire will gain SARcode's lifitegrast, an eye drop formulation of a small molecule LFA-1
12:00 AM, Jun 06, 2003  |  BC Extra | Company News

Biogen returns LFA-1 to Icos

ICOS will reacquire the sole rights to the LFA-1 program it had partnered with BGEN in …
2001. The most advanced compound in the partnership was IC747, an oral LFA-1 antagonist that recently …
do not warrant further development, and the company will begin preclinical development of more potent LFA-1
12:00 AM, Oct 18, 2002  |  BC Extra | Company News

Novartis, Tanabe LFA-1 deal

in the U.S., Europe and elsewhere to develop and market Tanabe's leukocyte function-associated antigen-1 ( LFA-1
Tanabe (Osaka, Japan) retains rights in Japan and certain other Asian countries. Clinical development of LFA-1

Pages